OPKO Health Q1 Revenue Falls 17% to $124.2M, Narrows Loss to $(0.07) EPS
OPK is trading near its 52-week low of $1.095 (5.9% above the low).
Summary
OPKO Health reported its first-quarter 2026 financial results, with revenues declining 17% year-over-year to $124.2 million, primarily attributed to a diagnostics divestiture and lower test volumes. Despite the revenue drop, the company significantly narrowed its net loss to $(0.07) per share, an improvement from $(0.10) in the prior year, driven by cost reductions and the strategic divestiture. This follows the company's previous 10-K which detailed a wider net loss for 2025. The mixed results indicate a strategic shift impacting top-line growth but improving bottom-line efficiency. Traders will closely watch the continued performance of its pharmaceutical segment and the long-term benefits of the diagnostics refocus.
At the time of this announcement, OPK was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $918.5M. The 52-week trading range was $1.10 to $1.60. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.